Vertex Pharmaceuticals Incorporated VRTX reported financial results for the fourth quarter on Wednesday.
Fourth quarter GAAP revenues came in at $144.6 million, above the expected revenue of $137.49 million and below the $351.2 million reported in the prior year period.
Total non-GAAP revenues for the fourth quarter of 2014 were $140.6 million, including $124.4 million in net product revenues from KALYDECO and $16.2 million from royalties and collaborative revenues.
The GAAP net loss for the fourth quarter of 2014 was $177 million, or $0.74 per share, which includes net charges of $45 million.
The non-GAAP net loss for the fourth quarter of 2014 was $132 million, or $0.55 per share, less than the expected loss of $0.65.
"The potential approval and launch of the combination of lumacaftor and ivacaftor and continued label and geographic expansion for KALYDECO are expected to significantly increase both the number of people treated with our medicines and our revenues to support the long-term growth of our business," said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex.
Vertex expects that its combined non-GAAP R&D and SG&A expenses in 2015 will be in the range of $1.05 to $1.10 billion.
Vertex Pharmaceuticals traded at $119.00 in the after-hours session, down 1.8 percent.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.